The effect of biweekly CHOP and standard CHOP in different subgroups of diffuse large B-cell lymphoma.
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Conventional chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone) seems unsatisfactory, so modifications of CHOP are used to improve the efficacy. DLBCL is a highly variable tumor, with different responses to therapy. The aim of this study is to explore the association between immunophenotype and treatment response.


METHODS
We analyzed the expression of Bcl-6, CD10, and MUM1 in 130 cases of DLBCL using immunohistochemistry. The cases were subdivided into germinal center B-cell-like (GCB) and non-GCB subtypes, and were randomly assigned to receive either 6-8 cycles of CHOP every 2 weeks or standard CHOP every 3 weeks.


RESULTS
After a median followup duration of 40 months, 3-year overall survival of biweekly CHOP was better than standard CHOP in the non-GCB group (58.3 vs. 38.6%, p < 0.05). However, the therapeutic effect of biweekly CHOP and standard CHOP was not different in the GCB group (64.8 vs. 57.5%, p > 0.05).


CONCLUSIONS
Immunohistochemistry analysis of different subgroups is useful to find the suitable therapy. Biweekly CHOP showed higher efficacy than standard treatment in the non-GCB subgroup.
Zhang
Qingyuan
Q
Department of Medical Oncology, The Affiliated Tumor Hospital of Harbin Medicial University, Daqing Oilfield General Hospital, China. wjxwsci@126.com
Wang
Jingxuan
J
Yu
Zhengyan
Z
Zhuang
Yongzhi
Y
Ma
Wenjie
W
Jin
Shi
S
Zhao
Shu
S
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002681:China / Q000453:epidemiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone